


PHARMACEUTICAL 2021

SCYNEXIS INC Rank 261 of 409







PHARMACEUTICAL 2021

SCYNEXIS INC Rank 261 of 409



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of SCYNEXIS INC is the variable Net Income, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is -218%, being 136% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	98,206
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,396
Liabilities, Non-Current	3,274
Other Assets	4,032
Other Compr. Net Income	0
Other Expenses	-3,148
Other Liabilities	50,108
Other Net Income	-7,184
Property and Equipment	298
Research and Development	36,522
Revenues	0
Selling, General and Administrative Expense	14,627

Output Variable	Value in 1000 USD
Assets	102,536
Liabilities	79,778
Expenses	48,001
Stockholders Equity	22,758
Net Income	-55,185
Comprehensive Net Income	-55,185
Economic Capital Ratio	-218%

